nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.10.2012 | General Gynecology

Botox^® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection

verfasst von: Roberta Granese, Giorgio Adile, Giorgio Gugliotta, Gaspare Cucinella, Salvatore Saitta, Biagio Adile

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To test the efficacy, duration and safety of 100 U of botulinum toxin type A (BoNT/A) in women affected by idiopathic detrusor overactivity (IDO) and the effectiveness of subsequent injections.

Methods

In this double centre, prospective study conducted from March 2008 to March 2010, we selected women affected by IDO who failed to respond to various antimuscarinic agents, reported intolerable anticholinergic side-effects or contraindication to their use, also without any response to tibial stimulation. Medical history, physical examination, standard urodynamic examination, urinalysis, urine culture, a 4-day voiding diary and a quality of life questionnaire were requested for all patients. A total amount of 100 U of BoNT/A were injected into the detrusor muscle. A second injection of BoNT/A was suggested to patients who experienced a relapse of initially improved symptoms.

Results

We enrolled a total number of 68 women. All patients showed significant improvement in urodynamic parameters, clinical features and quality of life, after the first injection of Botox^® until the 9 months of follow-up. Even after the second injection, with a follow-up of 3 months, we obtained results comparable with the first injection. Side-effects include an increase in post-void residual volume, dysuria and urinary infections.

Conclusions

We considered the dose of 100 U of Botox^®, for treatment of IDO, as an efficacious and safe solution compared to other therapeutic options, without serious and lasting adverse effects for women, even after a second injection.

van Ermengem E (1979) Classics in infectious diseases: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1:701–719PubMedCrossRef

Sahai A, Dowson C, Khan MS et al (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509–1515PubMedCrossRef

O’Brien CF (2002) Treatment of spasticity with botulinum toxin. Clin J Pain 18:S182–S190 (Review)PubMedCrossRef

Stöhrer M, Wolff A, Kramer G et al (2007) Seven years of botulinum toxin type A in the treatment of neurogenic detrusor hyperactivity. Urologe A 46:1211–1218PubMedCrossRef

Schmid DM, Roy S, Sulser T (2008) Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU Int 1:7–10CrossRef

Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644–650 (Review)PubMedCrossRef

Mohanty NK, Nayak RL, Alam M (2008) Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: single center experience. Indian J Urol 24:182–185PubMedCrossRef

de Groat WC (2004) The urothelium in overactive bladder: passive bystander or active participant? Urology 64:7–11 (Review)PubMedCrossRef

Chopra B, Barrick SR, Meyers S et al (2005) Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 562:859–871PubMedCrossRef

10.

De Sèze M, Ruffion A, Haab F et al (2008) Patient follow-up after botulinum toxin intradetrusor injection: proposal for management in neurogenic patients. Ann Readapt Med Phys 51:315–321PubMedCrossRef

11.

Abrams P, Cardozo L, Fall M et al (2002) Standardisation Sub-committee of the International Continence Society: the standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178PubMedCrossRef

12.

Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP (1996) Quality of life of persons with urinary incontinence: development of a new measure. Urology 147:67–71 (Discussion 71–72)CrossRef

13.

Gamé X, Mouracade P, Chartier-Kastler E et al (2009) Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 5:156–164PubMedCrossRef

14.

Brubaker L, Richter HE, Visco A et al (2008) Pelvic floor disorders network: refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217–222PubMedCrossRef

15.

Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ (2009) Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 113:1046–1051PubMed

16.

Mehnert U, Schurch B (2009) Botulinum toxin in nonneurogenic bladder dysfunction. Urologe A 48:233–244PubMedCrossRef

17.

Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245–1253PubMedCrossRef

18.

Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172:240–243PubMedCrossRef

19.

Kessler TM, Khan S, Panicker JN et al (2010) In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results. Eur Urol 57:879–883PubMedCrossRef

20.

Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697PubMedCrossRef

21.

Reitz A, Stöhrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515PubMedCrossRef

22.

Grosse J, Kramer G, Stöhrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659PubMedCrossRef

23.

Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177–185PubMedCrossRef

24.

Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ (2008) Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 54:181–187PubMedCrossRef

25.

Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528–535PubMedCrossRef

26.

Schurch B, de Sèze M, Denys P, Botox Detrusor Hyperreflexia Study Team et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200PubMedCrossRef

27.

Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850–858PubMedCrossRef

28.

White WM, Pickens RB, Doggweiler R, Klein FA (2008) Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 180:2522–2526PubMedCrossRef

Titel: Botox® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection
verfasst von: Roberta Granese
Giorgio Adile
Giorgio Gugliotta
Gaspare Cucinella
Salvatore Saitta
Biagio Adile
Publikationsdatum: 01.10.2012
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 4/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2349-8

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Botox^® for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection